

Congress Presidents

Claus Garbe, MD


Axel Hauschild, MD

M|E|L|A|N|O|M|A
2 0 1 3

www.worldmelanoma2013.com

8th World Congress of Melanoma

9th Congress of the European Association of Dermatooncology (EADO)
7th Interdisciplinary Melanoma/Skin Cancer Centers Meeting
3rd European Post-Chicago Melanoma Meeting 2013



**Preliminary
Program**

July 17–20, 2013
Hamburg, Germany
Congress Center Hamburg (CCH)



Advanced BCC: The challenges are more than skin deep

The consequences of advanced basal cell carcinoma (BCC) can be devastating for patients, especially if surgery is inappropriate or ineffective.¹⁻³ When current treatments are not a viable option...

What's next for these patients?

At Roche, we strive to address unmet medical needs to help patients live better lives.

Visit www.Roche.com for information about ongoing research and recent developments.

References: 1. Ting PT, et al. *J Cutan Med Surg.* 2005;9:10-15.
2. Goppner D, Leverkus M. *J Skin Cancer.* 2011;2011:650258.
Epub 2010 Dec 29. 3. Von Hoff DD, et al. *N Engl J Med.* 2009;361:1164-1172.



www.worldmelanoma2013.com

Welcome Message 4	Committees 5	Call for Abstracts 7
Preliminary Program Wednesday, July 17 8 Thursday, July 18 14 Friday, July 19 22 Saturday, July 20 28	General Information 34	Registration 35
	Accommodation 36	Travel Information 37

M|E|L|A|N|O|M|A
2 0 1 3

– As of March 2013 –

WELCOME MESSAGE



Dear colleagues and friends,

The World Congress of Melanoma was first held 1985 in Venice, and every four years since then it has attracted the international melanoma community of basic researchers and clinicians. The last World Congress of Melanoma took place in 2009 in Vienna and 1,000 participants attended this meeting. Now, in July 2013, the 8th World Congress of Melanoma will be organized in conjunction with the World Meeting of Melanoma Centers, the Post-Chicago Melanoma Meeting 2013 and the 9th Congress of the European Association of Dermato-Oncology. The latter event will be held at the end of the congress and includes non-melanoma skin cancer and cutaneous lymphomas as topics of this meeting. We are confident that this meeting in the International Congress Center in Hamburg will attract even more attendants than the previous congresses. This congress will cover the entire field of melanoma and other cutaneous malignancies. Epidemiology, prevention and early detection of skin cancer are important fields in order to reverse the current trend of increasing incidences. New diagnostic devices and optical approaches have improved the diagnostic sensitivity and specificity and are discussed extensively. Patient management issues including psychosocial aspects and the follow-up for high risk patients are aspects of the program too. Furthermore, basic science results for melanoma and other skin cancers will be presented in plenary lectures and during symposia.

This is an exciting time for the development of new drugs for melanoma treatment. New immunotherapies, selective kinase inhibitors, new vaccination approaches, and other innovative drugs and technologies are under development. Some have already been approved in 2011 and 2012 and others have

a great potential to gain approval in the near future. The leading experts and the entire community dedicated to melanoma treatment are highly excited about these innovations and are very interested in discussing further scenarios of drug development in melanoma. Other cutaneous malignancies are the main topic during the EADO sessions. Exciting new drugs and procedures have been developed for the treatment of actinic keratosis, which is the most frequent malignant lesion in man worldwide. Molecular targeting of the hedgehog pathway revolutionized the therapeutic approaches for basal cell carcinomas. Different novel strategies have been inaugurated for therapy of cutaneous lymphomas and for rare tumors like Merkel cell carcinoma and dermatofibrosarcoma protuberans. Thus, the congress addresses to the whole field of dermato-oncology.

The lively interaction between clinicians, experts in translational and basic research, and representatives of the pharmaceutical industry guarantees a successful outcome for every participant. International key opinion leaders will be invited to give overview presentations, to present the latest clinical trial results, and to discuss exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany. Please join us for this event and plan to submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you in Hamburg in July 2013!

Claus Garbe
Congress President

Axel Hauschild
Congress President

COMMITTEES

Congress Presidents

Claus Garbe (Tuebingen, DE)
Axel Hauschild (Kiel, DE)

Steering Committee

Anja Bosserhoff (Regensburg, DE)
Reinhard Dummer (Zurich, CH)
Jean-Jaques Grob (Marseille, FR)
Meenhard Herlyn (Philadelphia, US)
Roland Kaufmann (Frankfurt/Main, DE)
Grant McArthur (Melbourne, AU)
Hubert Pehamberger (Vienna, AT)
Dirk Schadendorf (Essen, DE)
Vernon Sondak (Tampa, US)

Invited Faculty

Sanjiv Agarwala (Bethlehem, US)
Petr Arenberger (Prague, CZ)
Giuseppe Argenziano (Naples, IT)
Dimitrios Bafaloukos (Athens, GR)
Boris Bastian (San Francisco, US)
Andrea Bauer (Dresden, DE)
Jürgen Bauer (Tuebingen, DE)
Jürgen Becker (Graz, AT)
Carola Berking (Munich, DE)
Mark Berneburg (Tuebingen, DE)
Michael Binder (Vienna, AT)
Andreas Blum (Konstanz, DE)
Anja Bosserhoff (Regensburg, DE)
Petra Boukamp (Heidelberg, DE)
Eckhard Breitbart (Buxtehude, DE)
Gabriela Cinat (Buenos Aires, AR)
Pippa Corrie (Cambridge, UK)
Veronique del Marmol (Brussels, BE)
Lev Demidov (Moscow, RU)
Thomas Diepgen (Heidelberg, DE)
Thomas Dirschka (Duesseldorf, DE)
Edgar Dippel (Ludwigshafen, DE)

Brigitte Dreno (Nantes, FR)
Reinhard Dummer (Zurich, CH)
Madeleine Duvic (Houston, US)
Friederike Egberts (Kiel, DE)
Alexander Eggermont (Paris, FR)
Thomas Eigentler (Tuebingen, DE)
Alexander Enk (Heidelberg, DE)
Enrique Espinosa (Madrid, ES)
Keith Flaherty (Boston, US)
Peter Friedl (Nijmegen, NL)
Thomas Gajewski (Chicago, US)
Alan Geller (Boston, US)
Jeffrey Gershenwald (Houston, US)
Colin Goding (Oxford, UK)
Helen Gogas (Athens, GR)
Stephan Grabbe (Mainz, DE)
Adele Green (Brisbane, AU)
Klaus Griewank (Essen, DE)
Jean-Jacques Grob (Marseille, FR)
Valerie Guild (Richmond, US)
Jun Guo (Beijing, CN)
Ralf Gutzmer (Hannover, DE)
Holger Haenssle (Göttingen, DE)
Allan Halpern (New York, US)
Johann Hansson (Stockholm, SE)
Rudolf Herbst (Erfurt, DE)
Meenhard Herlyn (Philadelphia, US)
Peter Hersey (Newcastle, AU)
Uwe Hillen (Essen, DE)
Peter Hirth (Berkeley, US)
Steven Hodi (Boston, US)
Katharina Kaehler (Kiel, DE)
Lidija Kandolf-Sekulovic (Belgrade, RS)
Mohammed Kashani-Sabet (San Francisco, US)
Alexander Katalinic (Luebeck, DE)
Roland Kaufmann (Frankfurt/Main, DE)
Richard Kefford (Sydney, AU)
Helmut Kerl (Graz, AT)
Ulrich Keilholz (Berlin, DE)
John Kirkwood (Pittsburgh, US)
Detlev Klemke (Mannheim, DE)

Robert Knobler (Vienna, AT)
 Oliver Kölbl (Regensburg, DE)
 Sven Krengel (Luebeck, DE)
 Rainer Kunstfeld (Vienna, AT)
 Mario Lacouture (New York, US)
 Jennifer Landsberg (Bonn, DE)
 Lionel Larue (Orsay, FR)
 Sancy Leachman (Salt Lake City, US)
 Celeste Lebbe (Paris, FR)
 Ulrike Leiter-Stöppke (Tuebingen, DE)
 Georgina Long (Sydney, AU)
 Isabel M. Longo Imedio (Madrid, ES)
 Carmen Loquai (Mainz, DE)
 Paul Lorigan (Manchester, UK)
 Marcus Maia (São Paulo, BR)
 Michele Maio (Sienna, IT)
 Josep Malvey (Barcelona, ES)
 Richard Marais (Manchester, UK)
 Ashfaq Marghoob (New York, US)
 Jerry Marsden (Birmingham, UK)
 Salvador Martin Algarra (Pamplona, ES)
 Eve Maubec (Paris, FR)
 Grant McArthur (Melbourne, AU)
 Friedegund Meier (Tuebingen, DE)
 Glen Merlino (Bethesda, US)
 Mark Middleton (Oxford, UK)
 Matthias Moehrle (Tuebingen, DE)
 Peter Mohr (Buxtehude, DE)
 Ingrid Moll (Hamburg, DE)
 Dorothee Nashan (Dortmund, DE)
 Julia Newton-Bishop (Leeds, UK)
 Judit Oláh (Szeged, HU)
 Hubert Pehamberger (Vienna, AT)
 Giovanni Pellacani (Modena, IT)
 Ketty Peris (L'Aquila, IT)
 Teresa Petrella (Toronto, CA)
 Michael Reusch (Hamburg, DE)
 Antoni Ribas (Los Angeles, US)
 Jason Rivers (Vancouver, CA)
 Caroline Robert (Paris, FR)
 Martin Rocken (Tuebingen, DE)

Alexander Roesch (Homburg, DE)
 Christian Sander (Hamburg, DE)
 Jacob Schachter (Tel Aviv, IL)
 Dirk Schadendorf (Essen, DE)
 Birgit Schitte (Tuebingen, DE)
 Erwin Schultz (Nuernberg, DE)
 Thomas Schwarz (Kiel, DE)
 Richard Scoyler (Sydney, AU)
 Aleksandar Sekulic (Scottsdale, US)
 Vernon Sondak (Tampa, US)
 Peter Soyer (Brisbane, AU)
 Alan Spatz (Montreal, CA)
 Rudolf Stadler (Minden, DE)
 Andreas Stang (Halle, DE)
 Hans Starz (Augsburg, DE)
 Eggert Stockfleth (Berlin, DE)
 Alexander Stratigos (Athens, GR)
 Rolf-Markus Szeimies (Recklinghausen, DE)
 Alessandro Testori (Milan, IT)
 John Thompson (Sydney, AU)
 Wolfgang Tilgen (Heidelberg, DE)
 Uwe Trefzer (Berlin, DE)
 Michael Tronnier (Hildesheim, DE)
 Hensin Tsao (Boston, US)
 Erwin Tschachler (Vienna, AT)
 Thomas Tüting (Bonn, DE)
 Selma Ugurel (Graz, AT)
 Martina Ulrich (Berlin, DE)
 Jens Ulrich (Quedlinburg, DE)
 Matthias Volkenandt (Munich, DE)
 Daniel Vorobiof (Johannesburg, ZA)
 Alberto Wainstein (Belo Horizonte, BR)
 Jeffrey Weber (Tampa, US)
 Michael Weichenthal (Kiel, DE)
 Benjamin Weide (Tuebingen, DE)
 Georg Weinlich (Innsbruck, AT)
 Julia Welzel (Augsburg, DE)
 Ann-Marie Wennberg (Gothenburg, SE)
 Jochen Werner (Marburg, DE)
 Dagmar Whitaker (Cape Town, ZA)

The scientific committee invites authors to submit their abstracts for consideration and inclusion in the program. Please submit your abstract on subjects relevant to the abstract topics online at www.worldmelanoma2013.com. Faxed or mailed abstracts will not be reviewed.

Preparation of your Abstract

- Abstracts must be submitted in English
- All abstracts must contain original work that has not been published or presented identically on previous occasions
- Indicate the preferred type of presentation (oral or poster)
- The title should be as brief as possible but long enough to indicate clearly the nature of the study. Abbreviations must not be used in the title
- Graphics or tables shall not be used
- Please check spelling and grammar carefully. All abstracts will be published as submitted
- Use generic names. Commercial drug names may not be used

Oral Presentations

Computer projection facilities (PowerPoint presentations) will be available in all meeting rooms. MCI will provide further information prior to the congress.

Poster Presentations

Selected posters will be discussed in a speaker's corner in the poster area of the CCH. Posters should be prepared in DIN A0 size (84 × 1189 mm), portrait format, in English language. MCI will provide further information prior to the congress.

Abstract Topics

Melanoma

- Preventive actions
- Diagnostics
- Genetics
- Treatments
- Follow-up
- Case reports
- Miscellaneous

Non-melanoma Skin Cancer

- Preventive actions
- Diagnostics
- Actinic keratoses
- Treatments
- Case reports
- Miscellaneous

Cutaneous Lymphomas

- Classification
- Diagnostics
- Treatments
- Case reports
- Miscellaneous

Important Contacts

Legal Organizer (PCO)

MCI Deutschland GmbH
 MCI – Berlin Office
 Annette Gleich
 Markgrafenstrasse 56
 10117 Berlin, Germany
 Phone: +49 (0)30 20 45 90
 Fax: +49 (0)30 20 45 950

General Information

congress@worldmelanoma2013.com

Scientific Program

secretariat@worldmelanoma2013.com

Registration, Accommodation

registration@worldmelanoma2013.com

Exhibition and Sponsorship

sponsors@worldmelanoma2013.com

	Hall G	Hall A	Hall B		Hall C	Hall F	
1:00 PM	1:00 PM–2:30 PM	1:00 PM–2:30 PM	1:00 PM–2:30 PM		1:00 PM–2:30 PM	1:00 PM–2:30 PM	
1:30 PM	SYMPOSIUM 1 Highlights from ASCO 2013 (I)	SYMPOSIUM 2 Melanoma genetics	SYMPOSIUM 3 Sentinel node biopsy: clinical outcomes		SYMPOSIUM 4 Sequential dermoscopy	SYMPOSIUM 5 PI3K-AKT pathway inhibition in melanoma	
2:00 PM							
2:30 PM							
3:00 PM	2:45 PM–3:45 PM	2:45 PM–3:45 PM	2:45 PM–3:45 PM		2:45 PM–3:45 PM	2:45 PM–3:45 PM	
3:30 PM	SYMPOSIUM 6 Highlights from ASCO 2013 (II)	SYMPOSIUM 7 New approaches to melanoma diagnosis	WORKSHOP 1 Sentinel node: evaluation and pathology		PANEL DISCUSSION 1 Melanocytic nevi: observation or excision?	WORKSHOP 2 Melanoma stem cells	
4:00 PM	COFFEE BREAK				COFFEE BREAK		
4:30 PM	4:15 PM–5:15 PM						
5:00 PM	SATELLITE SYMPOSIUM Bristol-Meyers Squibb GmbH & Co. KGaA						
5:30 PM	5:15 PM–7:15 PM	5:15 PM–6:15 PM	5:15 PM–6:15 PM		5:15 PM–6:15 PM	5:15 PM–7:15 PM	
6:00 PM	SYMPOSIUM 8 New drugs & trials for melanoma: a quick update (I)	WORKSHOP 3 Prognostic biomarkers	WORKSHOP 4 Management of congenital nevi		WORKSHOP 5 Transcriptional regulators in melanoma	FREE COMMUNICATIONS 1	
6:30 PM		6:15 PM–7:15 PM	6:15 PM–7:15 PM		6:15 PM–7:15 PM		
7:00 PM		WORKSHOP 6 Predictive biomarkers in melanoma	WORKSHOP 7 Atypical spitzoid tumors: benign or malignant?		WORKSHOP 8 Animal models for melanoma		
7:15 PM	NETWORKING EVENING				NETWORKING EVENING		

- Melanoma
- General skin cancer
- Epithelial skin cancer
- Cutaneous lymphoma and rare skin tumors

1:00 PM–2:30 PM	SYMPOSIUM 1
HALL G	Highlights from ASCO 2013 (I) Chairs: C. Garbe (Tuebingen, DE) K. Flaherty (Boston, US) <i>Immunotherapy</i> A. Ribas (Los Angeles, US) <i>Kinase inhibitors</i> G. Long (Sydney, AU) <i>Combined therapies</i> K. Flaherty (Boston, US)
1:00 PM–2:30 PM	SYMPOSIUM 2
HALL A	Melanoma genetics Chairs: B. Bastian (San Francisco, US) B. Schadendorf (Essen, DE)
1:00 PM–2:30 PM	SYMPOSIUM 3
HALL B	Sentinel node biopsy: clinical outcomes Chairs: F. Egberts (Kiel, DE) R. Gutzmer (Hannover, DE) A. Testori (Milan, IT)
1:00 PM–2:30 PM	SYMPOSIUM 4
HALL C	Sequential dermoscopy Chairs: M. Binder (Vienna, AT) H. Haenssle (Goettingen, DE)
1:00 PM–2:30 PM	SYMPOSIUM 5
HALL F	PI3K-AKT pathway inhibition in melanoma Chairs: S. Hodi (Boston, US) F. Meier (Tuebingen, DE)

2:45 PM–3:45 PM	SYMPOSIUM 6
HALL G	Highlights from ASCO 2013 (II) Chairs: A. Hauschild (Kiel, DE) R. Kefford (Sydney, AU) <i>Adjuvant treatment</i> R. Kirkwood (Pittsburgh, US) <i>Mutational screening</i> R. Kefford (Sydney, AU)
2:45 PM–3:45 PM	SYMPOSIUM 7
HALL A	New approaches to melanoma diagnosis Chairs: J. Malvehy (Barcelona, ES) G. Pellacani (Modena, IT)
2:45 PM–3:45 PM	WORKSHOP 1
HALL B	Sentinel node: evaluation and pathology Chairs: A. Spatz (Montreal, CA) H. Starz (Augsburg, DE)
2:45 PM–3:45 PM	PANEL DISCUSSION 1
HALL C	Melanocytic nevi: observation or excision? Chairs: J.-J. Grob (Marseille, FR) M. Reusch (Hamburg, DE) J. Rivers (Vancouver, CA)
2:45 PM–3:45 PM	WORKSHOP 2
HALL F	Melanoma stem cells Chairs: C. Goding (Oxford, UK) A. Roesch (Homburg, DE)
3:45 PM–4:15 PM	COFFEE BREAK

4:15 PM–5:15 PM	SATELLITE SYMPOSIUM
HALL G	Bristol-Meyers Squibb GmbH & Co. KGaA
5:15 PM–7:15 PM	SYMPOSIUM 8
HALL G	New drugs & trials for melanoma: a quick update (I)
	Chairs: G. Cinat (<i>Buenos Aires, AR</i>) A. Hauschild (<i>Kiel, DE</i>) T. Petrella (<i>Toronto, CA</i>)
5:15 PM–6:15 PM	WORKSHOP 3
HALL A	Prognostic biomarkers
	Chairs: C. Lebbe (<i>Paris, FR</i>) S. Ugurel (<i>Graz, AT</i>)
5:15 PM–6:15 PM	WORKSHOP 4
HALL B	Management of congenital nevi
	Chairs: S. Krenzel (<i>Luebeck, DE</i>) A. Marghoob (<i>New York, US</i>)
5:15 PM–6:15 PM	WORKSHOP 5
HALL C	Transcriptional regulators in melanoma
	Chairs: A. Bosserhoff (<i>Regensburg, DE</i>) B. Schitteck (<i>Tuebingen, DE</i>)
5:15 PM–7:15 PM	FREE COMMUNICATIONS 1
HALL F	Chairs: J. Oláh (<i>Szeged, HU</i>) U. Trefzer (<i>Berlin, DE</i>)

6:15 PM–7:15 PM	WORKSHOP 6
HALL A	Predictive biomarkers in melanoma
	Chairs: H. Gogas (<i>Athens, GR</i>) M. Kashani-Sabet (<i>San Francisco, US</i>)
6:15 PM–7:15 PM	WORKSHOP 7
HALL B	Atypical spitzoid tumors: benign or malignant?
	Chairs: J. Bauer (<i>Tuebingen, DE</i>) R. Scoyler (<i>Sydney, AU</i>)
6:15 PM–7:15 PM	WORKSHOP 8
HALL C	Animal models for melanoma
	Chairs: L. Larue (<i>Orsay, FR</i>) T. Tüting (<i>Bonn, DE</i>)
from 7:15 PM	NETWORKING EVENING

	Hall G	Hall A	Hall B		Hall C	Hall F	
8:00 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM		8:00 AM–9:30 AM	8:00 AM–9:30 AM	
8:30 AM	SYMPOSIUM 9 New drugs & trials for melanoma: a quick update (II)	SYMPOSIUM 10 Autologous T-cell transfer	SYMPOSIUM 11 Clinical and molecular pathology of melanoma		SYMPOSIUM 12 Melanoma susceptibility genes	FREE COMMUNICATIONS 2	
9:00 AM							
9:30 AM							
10:00 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM		9:45 AM–10:45 AM	9:45 AM–10:45 AM	
10:30 AM	PLENARY LECTURE 1 & 2 BRAF and MEK resistance/ Tumor dormancy	WORKSHOP 9 Vaccination: still a hopeful candidate?	WORKSHOP 10 UV protection		WORKSHOP 11 Mechanisms of resistance to immunotherapy	FREE COMMUNICATIONS 3 Late breaking abstracts	
11:00 AM	COFFEE BREAK				COFFEE BREAK		
11:30 AM	11:15 AM–12:45 PM	11:15 AM–12:45 PM	11:15 AM–12:45 PM		11:15 AM–12:45 PM	11:15 AM–12:45 PM	
12:00 PM	SYMPOSIUM 13 Towards a new melanoma classification	SYMPOSIUM 14 Immunotherapy with co-stimulatory molecules	SYMPOSIUM 15 Skin cancer awareness campaigns around the world		SYMPOSIUM 16 Kinase inhibitors combined with immunotherapy	DIFFICULT CASES 1 Difficult to diagnose cases	
12:30 PM							
1:00 PM	1:00 PM–2:00 PM	LUNCH BREAK			LUNCH BREAK		
1:30 PM	SATELLITE SYMPOSIUM F. Hoffmann-La Roche Ltd.						
2:00 PM	2:00 PM–3:00 PM	2:00 PM–3:00 PM	2:00 PM–3:00 PM		2:00 PM–3:00 PM	2:00 PM–3:00 PM	
2:30 PM	PLENARY LECTURE 3 & 4 How to communicate bad news to patients?/ Skin cancer in albinos	WORKSHOP 12 Oncology drug reimbursement issues	WORKSHOP 13 Topical sun screens: protection or promotion of skin cancer?		WORKSHOP 14 Combined treatment approaches	FREE COMMUNICATIONS 4	
3:00 PM		3:00 PM–4:00 PM			3:00 PM–4:00 PM	3:00 PM–4:00 PM	
3:30 PM		SATELLITE SYMPOSIUM Almirall			SATELLITE SYMPOSIUM Celgene Corporation	SATELLITE SYMPOSIUM ONCOSEC	
4:00 PM							
4:30 PM	COFFEE BREAK				COFFEE BREAK		
5:00 PM	4:30 PM–6:00 PM	4:30 PM–6:00 PM	4:30 PM–6:00 PM		4:30 PM–6:00 PM	4:30 PM–6:00 PM	
5:30 PM	SYMPOSIUM 17 MAP kinase pathway inhibition	PANEL DISCUSSION 2 Chemotherapy for advanced melanoma: still an option?	SYMPOSIUM 18 Management of cutaneous adverse events		SYMPOSIUM 19 Mutational screening: how it should be done	WORKSHOP 15 Epidemiology of melanoma	
6:00 PM							

- Melanoma
- General skin cancer
- Epithelial skin cancer
- Cutaneous lymphoma and rare skin tumors

8:00 AM–9:30 AM	SYMPOSIUM 9
HALL G	New drugs & trials for melanoma: a quick update (II) Chairs: C. Garbe (Tuebingen, DE) G. Long (Sydney, AU) M. Maio (Sienna, IT)
8:00 AM–9:30 AM	SYMPOSIUM 10
HALL A	Autologous T-cell transfer Chairs: B. Dreno (Nantes, FR) J. Schachter (Tel Aviv, IL)
8:00 AM–9:30 AM	SYMPOSIUM 11
HALL B	Clinical and molecular pathology of melanoma Chairs: B. Bastian (San Francisco, US) A. Spatz (Montreal, CA)
8:00 AM–9:30 AM	SYMPOSIUM 12
HALL C	Melanoma susceptibility genes Chairs: S. Leachman (Salt Lake City, US) J. Newton-Bishop (Leeds, UK) H. Tsao (Boston, US)
8:00 AM–9:30 AM	FREE COMMUNICATIONS 2
HALL F	Chairs: D. Nashan (Dortmund, DE) J. Ulrich (Quedlinburg, DE)

9:45 AM–10:45 AM	PLENARY LECTURES 1 & 2
HALL G	Chair: A. Bosserhoff (Regensburg, DE) <i>BRAF and MEK resistance</i> R. Marais (Manchester, UK) <i>Tumor dormancy</i> M. Rocken (Tuebingen, DE)
9:45 AM–10:45 AM	WORKSHOP 9
HALL A	Vaccination: still a hopeful candidate? Chairs: P. Hersey (Newcastle, AU) J. Weber (Tampa, US)
9:45 AM–10:45 AM	WORKSHOP 10
HALL B	UV protection Chairs: M. Berneburg (Tuebingen, DE) V. del Marmol (Brussels, BE)
9:45 AM–10:45 AM	WORKSHOP 11
HALL C	Mechanisms of resistance to immunotherapy Chairs: J. Landsberg (Bonn, DE) T. Gajewski (Chicago, US)
9:45 AM–10:45 AM	FREE COMMUNICATIONS 3
HALL F	Late breaking abstracts Chairs: K. Kaehler (Kiel, DE) F. Meier (Tuebingen, DE)
10:45 AM–11:15 AM	COFFEE BREAK

11:15 AM–12:45 PM	SYMPOSIUM 13
HALL G	Towards a new melanoma classification Chairs: A. Eggermont (<i>Paris, FR</i>) J. Gershenwald (<i>Houston, US</i>) J. Hansson (<i>Stockholm, SE</i>)
11:15 AM–12:45 PM	SYMPOSIUM 14
HALL A	Immunotherapy with co-stimulatory molecules Chairs: M. Maio (<i>Sienna, IT</i>) A. Ribas (<i>Los Angeles, US</i>)
11:15 AM–12:45 PM	SYMPOSIUM 15
HALL B	Skin cancer awareness campaigns around the world Chairs: R. Stadler (<i>Minden, DE</i>) A. Wainstein (<i>Belo Horizonte, BR</i>) D. Whitaker (<i>Cape Town, ZA</i>)
11:15 AM–12:45 PM	SYMPOSIUM 16
HALL C	Kinase inhibitors combined with immunotherapy Chairs: J. Weber (<i>Tampa, US</i>) S. Grabbe (<i>Mainz, DE</i>)
11:15 AM–12:45 PM	DIFFICULT CASES 1
HALL F	Difficult to diagnose cases Chairs: J. Malvehy (<i>Barcelona, ES</i>) G. Argenziano (<i>Naples, IT</i>) M. Maia (<i>São Paulo, BR</i>)
1:00 PM–2:00 PM	SATELLITE SYMPOSIUM
HALL G	F. Hoffmann-La Roche Ltd.
1:00 PM–2:00 PM	LUNCH BREAK

2:00 PM–3:00 PM	PLENARY LECTURES 3 & 4
HALL G	Chair: W. Tilgen (<i>Heidelberg, DE</i>) <i>How to communicate bad news to patients?</i> M. Volkenandt (<i>Munich, DE</i>) <i>Skin cancer in albinos</i> R. Kaufmann (<i>Frankfurt/Main, DE</i>)
2:00 PM–3:00 PM	WORKSHOP 12
HALL A	Oncology drug reimbursement issues Chairs: S. Argawala (<i>Bethlehem, US</i>) G. McArthur (<i>Melbourne, AU</i>) M. Middleton (<i>Oxford, UK</i>)
2:00 PM–3:00 PM	WORKSHOP 13
HALL B	Topical sun screens: protection or promotion of skin cancer? Chairs: C. Garbe (<i>Tuebingen, DE</i>) E. Tschachler (<i>Vienna, AT</i>)
2:00 PM–3:00 PM	WORKSHOP 14
HALL C	Combined treatment approaches Chairs: P. Lorigan (<i>Manchester, UK</i>) D. Schadendorf (<i>Essen, DE</i>)
2:00 PM–3:00 PM	FREE COMMUNICATIONS 4
HALL F	Chairs: R. Herbst (<i>Erfurt, DE</i>) L. Kandolf-Sekulovic (<i>Belgrade, RS</i>)
3:00 PM–4:00 PM	SATELLITE SYMPOSIUM
HALL A	Almirall
3:00 PM–4:00 PM	SATELLITE SYMPOSIUM
HALL C	Celgene Corporation
3:00 PM–4:00 PM	SATELLITE SYMPOSIUM
HALL F	ONCOSEC
4:00 PM–4:30 PM	COFFEE BREAK

4:30 PM–6:00 PM SYMPOSIUM 17

HALL G

MAP kinase pathway inhibition

Chairs: S. Martin Algarra (*Pamplona, ES*)
K. Flaherty (*Boston, US*)
G. McArthur (*Melbourne, AU*)

4:30 PM–6:00 PM PANEL DISCUSSION 2

HALL A

Chemotherapy for advanced melanoma: still an option?

Chairs: S. Agarwala (*Bethlehem, US*)
E. Espinosa (*Madrid, ES*)
H. Pehamberger (*Vienna, AT*)

4:30 PM–6:00 PM SYMPOSIUM 18

HALL B

Management of cutaneous adverse events

Chairs: M. Lacouture (*New York, US*)
C. Robert (*Paris, FR*)

4:30 PM–6:00 PM SYMPOSIUM 19

HALL C

Mutational screening: how it should be done

Chairs: A. Enk (Heidelberg, DE)
R. Scoyler (Camperstown, AU)

4:30 PM–6:00 PM WORKSHOP 15

HALL F

Epidemiology of melanoma

Chairs: A. Green (Brisbane, AU)
A. Katalinic (Luebeck, DE)

	Hall G	Hall A	Hall B		Hall C	Hall F	
8:00 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM		8:00 AM–9:30 AM	8:00 AM–9:30 AM	
8:30 AM	SYMPOSIUM 20 Adjuvant treatment	SYMPOSIUM 21 Research in epithelial skin cancer: what's new?	SYMPOSIUM 22 Management of brain metastasis		SYMPOSIUM 23 Melanoma centers logistics	FREE COMMUNICATIONS 5	
9:00 AM							
9:30 AM							
10:00 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM		9:45 AM–10:45 AM	9:45 AM–10:45 AM	
10:30 AM	PLENARY LECTURES 5 & 6 Photocarcinogenesis/ UVA and melanoma development	WORKSHOP 16 What's new for basal cell carcinomas?	WORKSHOP 17 Ocular melanomas: new treatment opportunities		WORKSHOP 18 Melanoma foundations	DIFFICULT CASES 2 Difficult to diagnose cases	
11:00 AM	COFFEE BREAK				COFFEE BREAK		
11:30 AM	11:15 AM–12:45 PM	11:15 AM–12:45 PM	11:15 AM–12:45 PM		11:15 AM–12:45 PM	11:15 AM–12:45 PM	
12:00 PM	SYMPOSIUM 24 Loco regional melanoma treatment	SYMPOSIUM 25 Squamous cell carcinomas of the skin: conventional and future treatment opportunities	SYMPOSIUM 26 Childhood melanoma		SYMPOSIUM 27 Melanoma follow-up	DIFFICULT CASES 3 Difficult to treat cases (metastatic melanoma)	
12:30 PM							
1:00 PM	1:00 PM–2:00 PM	LUNCH BREAK			LUNCH BREAK		
1:30 PM	SATELLITE SYMPOSIUM Merck Sharp & Dohme Corp.						
2:00 PM		2:00 PM–3:00 PM				2:00 PM–3:00 PM	
2:30 PM		SATELLITE SYMPOSIUM MELA Sciences				SATELLITE SYMPOSIUM F. Hoffmann-La Roche Ltd.	
3:00 PM							
3:30 PM	COFFEE BREAK				COFFEE BREAK		
4:00 PM	3:30 PM–4:30 PM	3:30 PM–4:30 PM	3:30 PM–4:30 PM		3:30 PM–4:30 PM	3:30 PM–4:30 PM	
4:30 PM	PLENARY LECTURES 7 & 8 From identifying a target to an approved targeted therapy/Cancer invasion and the microenvironment: plasticity and reciprocity	SYMPOSIUM 28 Actinic keratoses: surgical and ablative treatments	SYMPOSIUM 29 Mucosal melanoma		SYMPOSIUM 30 Melanoma around the world	FREE COMMUNICATIONS 6	

- Melanoma
- General skin cancer
- Epithelial skin cancer
- Cutaneous lymphoma and rare skin tumors

8:00 AM–9:30 AM	SYMPOSIUM 20
HALL G	Adjuvant treatment Chairs: P. Corrie (<i>Cambridge, UK</i>) J. Kirkwood (<i>Pittsburg, US</i>) P. Mohr (<i>Buxtehude, DE</i>)
8:00 AM–9:30 AM	SYMPOSIUM 21
HALL A	Research in epithelial skin cancer: what's new? Chairs: P. Boukamp (<i>Heidelberg, DE</i>) R. Kunstfeld (<i>Vienna, AT</i>)
8:00 AM–9:30 AM	SYMPOSIUM 22
HALL B	Management of brain metastasis Chairs: R. Kefford (<i>Sydney, AU</i>) C. Lebbe (<i>Paris, FR</i>)
8:00 AM–9:30 AM	SYMPOSIUM 23
HALL C	Melanoma centers logistics Chairs: T. Eigentler (<i>Tuebingen, DE</i>) V. Sondak (<i>Tampa, US</i>) J. Thompson (<i>Sydney, AU</i>)
8:00 AM–9:30 AM	FREE COMMUNICATIONS 5
HALL F	Chairs: E. Schultz (<i>Nuernberg, DE</i>) M. Tronnier (<i>Hildesheim, DE</i>)
9:45 AM–10:45 AM	PLENARY LECTURES 5 & 6
HALL G	Chair: M. Rocken (<i>Tuebingen, DE</i>) <i>Photocarcinogenesis</i> T. Schwarz (<i>Kiel, DE</i>) <i>UV radiation and melanoma development</i> G. Merlino (<i>Bethesda, US</i>)
9:45 AM–10:45 AM	WORKSHOP 16
HALL A	What's new for basal cell carcinomas? Chairs: K. Kaehler (<i>Kiel, DE</i>) A. Sekulic (<i>Scottsdale, US</i>)

9:45 AM–10:45 AM	WORKSHOP 17
HALL B	Ocular melanomas: new treatment opportunities Chairs: K. Griewank (<i>Essen, DE</i>) U. Keilholz (<i>Berlin, DE</i>)
9:45 AM–10:45 AM	WORKSHOP 18
HALL C	Melanoma foundations Chairs: V. Guild (<i>Richmond, US</i>) R. Kaufmann (<i>Frankfurt/Main, DE</i>)
9:45 AM–10:45 AM	DIFFICULT CASES 2
HALL F	Difficult to diagnose cases Chairs: J. Malvehy (<i>Barcelona, ES</i>) G. Argenziano (<i>Naples, IT</i>) M. Maia (<i>São Paulo, BR</i>)
10:45 AM–11:15 AM	COFFEE BREAK
11:15 AM–12:45 PM	SYMPOSIUM 24
HALL G	Loco regional melanoma treatment Chairs: V. Sondak (<i>Tampa, US</i>) B. Weide (<i>Tuebingen, DE</i>)
11:15 AM–12:45 PM	SYMPOSIUM 25
HALL A	Squamous cell carcinomas of the skin: conventional and future treatment opportunities Chairs: R. Kaufmann (<i>Frankfurt/Main, DE</i>) E. Maubec (<i>Paris, FR</i>)
11:15 AM–12:45 PM	SYMPOSIUM 26
HALL B	Childhood melanoma Chairs: J. Bauer (<i>Tuebingen, DE</i>) C. Berking (<i>Munich, DE</i>)
11:15 AM–12:45 PM	SYMPOSIUM 27
HALL C	Melanoma follow-up Chairs: A. Eggermont (<i>Paris, FR</i>) U. Leiter-Stöppke (<i>Tuebingen, DE</i>)

11:15 AM–12:45 PM	DIFFICULT CASES 3
HALL F	Difficult to treat cases (metastatic melanoma) Chair: D. Bafaloukos (Athens, GR) D. Vorobiof (Johannesburg, ZA)
1:00 PM–2:00 PM	SATELLITE SYMPOSIUM
HALL G	Merck Sharp & Dohme Corp.
1:00 PM–2:00 PM	LUNCH BREAK
2:00 PM–3:00 PM	SATELLITE SYMPOSIUM
HALL A	MELA Sciences
2:00 PM–3:00 PM	SATELLITE SYMPOSIUM
HALL F	F. Hoffmann-La Roche Ltd.
3:00 PM–3:30 PM	COFFEE BREAK
3:30 PM–4:30 PM	PLENARY LECTURES 7 & 8
HALL G	Chair: A. Hauschild (Kiel, DE) <i>From identifying a target to an approved targeted therapy</i> P. Hirth (Berkeley, US) <i>Cancer invasion and the microenvironment: plasticity and reciprocity</i> P. Friedl (Nijmegen, NL)
3:30 PM–4:30 PM	SYMPOSIUM 28
HALL A	Actinic keratoses: surgical and ablative treatments Chairs: J. Marsden (Birmingham, UK) K. Peris (L'Aquila, IT)

3:30 PM–4:30 PM	SYMPOSIUM 29
HALL B	Mucosal melanoma Chairs: J. Guo (Beijing, CN) J. Werner (Marburg, DE)
3:30 PM–4:30 PM	SYMPOSIUM 30
HALL C	Melanoma around the world Chairs: L. Demidov (Moscow, RU) A. Wainstein (Belo Horizonte, BR) D. Whitaker (Cape Town, ZA)
3:30 PM–4:30 PM	FREE COMMUNICATIONS 6
HALL F	Chairs: I. M. Longo Imedio (Madrid, ES) C. Loquai (Mainz, DE)

	Hall G	Hall A	Hall B		Hall C	Hall F	
8:00 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM	8:00 AM–9:30 AM		8:00 AM–9:30 AM	8:00 AM–9:30 AM	
8:30 AM	SYMPOSIUM 31 Epidemiology of skin cancer: a global perspective	SYMPOSIUM 32 Diagnosis and classification of cutaneous lymphomas	SYMPOSIUM 33 Tele dermatology for skin cancer: fact or fiction?		SYMPOSIUM 34 Actinic keratoses: topical treatments	SYMPOSIUM 35 In vivo confocal laser microscopy	
9:00 AM							
9:30 AM							
10:00 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM	9:45 AM–10:45 AM		9:45 AM–10:45 AM	9:45 AM–10:45 AM	
10:30 AM	PLENARY LECTURES 9 & 10 Stem transplantation for advanced CTCL/ Primary prevention and public education	WORKSHOP 19 Doctor's iPhone: useful apps for skin cancer	WORKSHOP 20 Skin cancer in professional sportsmen		WORKSHOP 21 Merkel cell carcinoma	FREE COMMUNICATIONS 7	
11:00 AM	COFFEE BREAK				COFFEE BREAK		
11:30 AM	11:15 AM–12:45 PM	11:15 AM–12:45 PM	11:15 AM–12:45 PM		11:15 AM–12:45 PM	11:15 AM–12:45 PM	
12:00 PM	PANEL DISCUSSION 4 Is population screening worthwhile?	SYMPOSIUM 36 Treatment of cutaneous lymphomas	SYMPOSIUM 37 Photodynamic therapy (PDT): what's new?		SYMPOSIUM 38 Immunosuppression and skin cancer	SYMPOSIUM 39 International skin cancer guidelines	
12:30 PM							
1:00 PM	LUNCH BREAK				LUNCH BREAK		
1:30 PM							
2:00 PM	2:00 PM–3:00 PM	2:00 PM–3:00 PM	2:00 PM–3:00 PM		2:00 PM–3:00 PM	2:00 PM–5:00 PM	
2:30 PM	PANEL DISCUSSION 3 Actinic keratoses: is it SCC in-situ?	WORKSHOP 22 Extracorporeal photophoresis (ECP): for which indication?	WORKSHOP 23 Skin cancer: an occupational disease?		WORKSHOP 24 Cutaneous sarcomas	PATIENTENSEMINAR/ PATIENTS' SEMINAR IN GERMAN Heller und schwarzer Hautkrebs	
3:00 PM	3:00 PM–3:30 PM						
3:30 PM	Closing remarks						
4:00 PM							
4:30 PM							
5:00 PM							

■ Melanoma
■ General skin cancer
■ Epithelial skin cancer
■ Cutaneous lymphoma and rare skin tumors

8:00 AM–9:30 AM	SYMPOSIUM 31
HALL G	Epidemiology of skin cancer: a global perspective Chairs: A. Green (<i>Brisbane, AU</i>) A. Stang (<i>Halle/Saale, DE</i>)
8:00 AM–9:30 AM	SYMPOSIUM 32
HALL A	Diagnosis and classification of cutaneous lymphomas Chairs: C.-D. Klemke (<i>Mannheim, DE</i>) R. Knobler (<i>Vienna, AT</i>)
8:00 AM–9:30 AM	SYMPOSIUM 33
HALL B	Teledermatology for skin cancer: fact or fiction? Chairs: A. Blum (<i>Konstanz, DE</i>) P. Soyer (<i>Brisbane, AU</i>)
8:00 AM–9:30 AM	SYMPOSIUM 34
HALL C	Actinic keratoses: topical treatments Chairs: C. Berking (<i>Munich, DE</i>) A. Stratigos (<i>Athens, GR</i>)
8:00 AM–9:30 AM	SYMPOSIUM 35
HALL F	In vivo confocal laser microscopy Chairs: M. Ulrich (<i>Berlin, DE</i>) J. Welzel (<i>Augsburg, DE</i>)
9:45 AM–10:45 AM	PLENARY LECTURES 9 & 10
HALL G	Chair: R. Stadler (<i>Minden, DE</i>) <i>Stem transplantation for advanced CTCL</i> M. Duvic (<i>Houston, US</i>) <i>Primary prevention and public education</i> A. Halpern (<i>New York, US</i>)

9:45 AM–10:45 AM	WORKSHOP 19
HALL A	Doctor's iPhone: useful apps for skin cancer Chair: T. Eigentler (<i>Tuebingen, DE</i>) G. Pellacani (<i>Modena, IT</i>)
9:45 AM–10:45 AM	WORKSHOP 20
HALL B	Skin cancer in professional sportsmen Chairs: T. Dirschka (<i>Duesseldorf, DE</i>) M. Moehrle (<i>Tuebingen, DE</i>)
9:45 AM–10:45 AM	WORKSHOP 21
HALL C	Merkel cell carcinoma Chairs: J. Becker (<i>Graz, AT</i>) C. Lebbe (<i>Paris, FR</i>)
9:45 AM–10:45 AM	FREE COMMUNICATIONS 7
HALL F	Chair: U. Hillen (<i>Essen, DE</i>) G. Weinlich (<i>Innsbruck, AT</i>)
10:45 AM–11:15 AM	COFFEE BREAK
11:15 AM–12:45 PM	PANEL DISCUSSION 4
HALL G	Is population screening worthwhile? Chairs: E. Breitbart (<i>Buxtehude, DE</i>) A. Geller (<i>Boston, US</i>)
11:15 AM–12:45 PM	SYMPOSIUM 36
HALL A	Treatment of cutaneous lymphomas Chairs: E. Dippel (<i>Ludwigshafen, DE</i>) R. Dummer (<i>Zurich, CH</i>)

11:15 AM–12:45 PM	SYMPOSIUM 37
HALL B	Photodynamic therapy (PDT): what's new? Chairs: R.-M. Szeimies (<i>Recklinghausen, DE</i>) A.-M. Wennberg (<i>Gothenburg, SE</i>)
11:15 AM–12:45 PM	SYMPOSIUM 38
HALL C	Immunosuppression and skin cancer Chairs: U. Hillen (<i>Essen, DE</i>) E. Stockfleth (<i>Berlin, DE</i>)
11:15 AM–12:45 PM	SYMPOSIUM 39
HALL F	International skin cancer guidelines Chairs: C. Garbe (<i>Tuebingen, DE</i>) J. Thompson (<i>Sydney, AU</i>)
1:00 PM–2:00 PM	LUNCH BREAK
2:00 PM–3:00 PM	PANEL DISCUSSION 3
HALL G	Actinic Keratoses: is it SCC in-situ? Chairs: H. Kerl (<i>Graz, AT</i>) M. Reusch (<i>Hamburg, DE</i>)
2:00 PM–3:00 PM	WORKSHOP 22
HALL A	Extracorporeal Photophoresis (ECP): for which indication? Chairs: U. Hillen (<i>Essen, DE</i>) M. Weichenthal (<i>Kiel, DE</i>)

2:00 PM–3:00 PM	WORKSHOP 23
HALL B	Skin cancer: an occupational disease? Chairs: A. Bauer (<i>Dresden, DE</i>) T. Diepgen (<i>Heidelberg, DE</i>)
2:00 PM–3:00 PM	WORKSHOP 24
HALL C	Cutaneous sarcomas Chairs: P. Arenberger (<i>Prague, CZ</i>) S. Ugurel (<i>Graz, AT</i>)
2:00 PM–5:00 PM	PATIENTENSEMINAR/PATIENTS' SEMINAR IN GERMAN
HALL F	Heller und schwarzer Hautkrebs Chairs: I. Moll (<i>Hamburg, DE</i>) C. Sander (<i>Hamburg, DE</i>) Co-Chairs: K. Kaehler (<i>Kiel, DE</i>) P. Mohr (<i>Buxtehude, DE</i>) M. Reusch (<i>Hamburg, DE</i>)
3:00 PM–3:30 PM	CLOSING REMARKS
HALL G	

GENERAL INFORMATION



Congress Presidents

Prof. Dr. med. Claus Garbe
University Skin Cancer Clinic Tuebingen
Liebermeisterstrasse 20
72076 Tuebingen, Germany

Prof. Dr. med. Axel Hauschild
University Hospital Schleswig-Holstein
Department of Dermatology, Campus Kiel
Schittenhelmstrasse 7
24105 Kiel, Germany

Congress Venue

CCH • Congress Center Hamburg
Am Dammtor/Marseiller Strasse
20355 Hamburg, Germany

Legal Organizer (PCO)

MCI Deutschland GmbH
MCI – Berlin Office
Markgrafenstrasse 56
10117 Berlin, Germany
Phone: +49 (0)30 20 45 90
Fax: +49 (0)30 20 45 950
congress@worldmelanoma2013.com

CME Accreditation

An application for CME accreditation will be made.

Official Language

The congress language is English.

Letter of Invitation

Those persons needing an official invitation letter in order to attend the congress may contact Astrid Schörnig: secretariat@worldmelanoma2013.com specifying the necessary details. The letter of invitation does not financially obligate the congress organizers in any way.

Exhibition

The scientific meeting will be accompanied by a comprehensive industrial exhibition covering the latest developments in diagnosis and therapy. Companies interested in joining the exhibition are kindly asked to contact MCI Deutschland GmbH at: sponsors@worldmelanoma2013.com.

Key Dates to Remember

Deadline abstract submission	March 24, 2013
Notification of acceptance of abstracts	May 16, 2013
Deadline early registration	May 16, 2013
Deadline for pre-registration	June 26, 2013

REGISTRATION

	Very Early until February 14, 2013	Early February 14, 2013 to May 16, 2013	Late from May 17, 2013
Participant	€ 500.–	€ 600.–	€ 700.–
Resident	€ 500.–	€ 600.–	€ 700.–
Student	€ 130.–	€ 160.–	€ 190.–
Day ticket (July 18, 19, 20)	€ 250.–	€ 250.–	€ 250.–
Accompanying person(s)	€ 85.–	€ 85.–	€ 85.–

Participants and accompanying persons are kindly asked to register in advance preferably by using the online portal on the congress website. Registration is also possible via fax or regular mail. The registration form and further information are available at www.worldmelanoma2013.com.

Registration Fee for Delegates Covers

- Admission to scientific sessions and satellite symposia
- Collection of abstracts (either on hard copy or CD-ROM)
- Congress bag with congress documents
- Networking evening
- Admission to exhibition

Deadline for pre-registration is June 26, 2013. All fees are indicated in Euro, incl. VAT. Registration on site is possible during the entire congress within the opening hours of the registration counter. Registration and services booked can only be confirmed after receipt of full prepayment or valid credit card details.

Cancellation Policy

In case of cancellation of participation until May 17, 2013 registration fees will be refunded deducting a handling fee of € 32.– per person. Cancellations received from May 17, 2013 cannot be refunded. Name changes will be charged with € 20.– per registration. In case of any special requests for the processing of your invoice, kindly let us know when returning your registration form. For the rewriting of invoices € 20.– will be charged.

Method of Payment

Payments should be made

- by credit cards (American Express, Eurocard/MasterCard, Visa),
- by direct debits order via German bank accounts only,
- in cash on site.

ACCOMMODATION

Hotels	Single Room	Double Room	Distance to CCH
Radisson Blu Hotel****	€ 175.–	€ 195.–	0 km
Grand Elysee Hamburg*****	€ 180.–	€ 200.–	0.9 km
Mercure Hotel Hamburg Mitte****	€ 159.–		1.4 km
Novotel Hamburg Alster****	€ 157.–	€ 175.–	4.6 km
Scandic Hamburg Emporio****	€ 149.–	€ 169.–	0.9 km
Hotel Alster-Hof***	€ 80.–	€ 120.–	0.4 km
Hotel Ibis Hamburg Alster**	€ 140.–	€ 160.–	1.4 km

* Rates per room and night including breakfast and German VAT.

Participants are kindly asked to make hotel reservations by using the online registration portal on the congress website. Hotel reservation is also possible via fax or regular mail. The registration form and further information are available at www.worldmelanoma2013.com. The selected hotels have limited capacities. It is recommended to make your hotel booking as early as possible.

Method of Payment

All nights will be charged upon registration. All further nights as well as extras have to be paid directly at the hotel upon check-out. The city of Hamburg will possibly be introducing a tourist or bed tax in the coming months. This tax, if applicable, will be calculated separately at a later time. The following credit cards are accepted: MasterCard, Visa, American Express. If the desired hotel is already fully booked, MCI Deutschland GmbH reserves the right to arrange accommodation in another hotel.

Cancellation Policy

Cancellations or changes should be received in writing to MCI Deutschland

GmbH by e-mail or fax. In case of changes a handling fee (€ 30.–) applies. Please do not contact the hotel directly.

Cancellation of room/nights received before January 14, 2013:

- Refund deducting a € 40.– cancellation fee

Cancellation of room/nights received until March 15, 2013:

- Cancellation of one night: no refund
- Cancellation of two or more nights: 50% refund of booked nights

Cancellation of room/nights received from March 16, 2013 or no-show:

- No refund

Group Bookings

For group bookings (20 rooms or more) please contact MCI Deutschland GmbH:

Phone: +49 (0)30 20 45 90
congress@worldmelanoma2013.com

For updated information on accommodation please visit the congress website www.worldmelanoma2013.com.

TRAVEL INFORMATION

Congress Venue

CCH • Congress Center Hamburg
 Am Dammtor/Marseiller Strasse
 20355 Hamburg, Germany

Air Travel

From Hamburg Airport, 69 airlines fly directly to 18 national and 98 international destinations. It is situated in the north of the city in Fuhlsbüttel. For detailed flight connections, please visit www.airport.de/en. From the airport the CCH can be reached by rapid transit (S-Bahn) line S1 and taxi. The journey time to the CCH by car is about 20 min and by public transport about 25 min.

Rail Travel

The CCH is located right next to Dammtor InterCity rail station for the high-speed trains of German rail and international rail connections. From Hamburg Central Station (Hauptbahnhof), take rapid transit (S-Bahn) line S21 (towards Elbgaustrasse). It is just one stop to Dammtor and takes only 2 min. From Dammtor Station, it is only a two-minute walk to the CCH.

Environmentally friendly – travel conveniently by train to the 8th World Congress of Melanoma from € 99.–

In cooperation with MCI Deutschland GmbH and Deutsche Bahn you can travel safely and conveniently to the 8th World Congress of Melanoma. By using the train for your journey you contribute to saving the environment. The price for your event ticket for a return trip to Hamburg is:

- 2nd class € 99.–
- 1st class € 159.–

The event ticket is valid from July 15 to 23, 2013. Please book your trip via telephone +49 (0)1805 31 11 53 and keep your credit card ready. Keyword: "WCM". For further information, please visit www.worldmelanoma2013.com.

Road Travel

It is best to take the motorways and exits shown below. Then follow the signs to "Messe/CCH".

- A7 from the North, A23 from the North-West and A1 from the South-West via A7/Elbtunnel: Junction HH-Volkspark
- A24/A1 from the East/North East: Junction HH-Horn
- A250/A255 from the South-East and A7 from the South: Via Neue Elbbrücken/HH-Zentrum

Parking Facilities

The underground garage East offers about 900 spaces. A central multi-story car park in Lagerstrasse also offers about 900 spaces at an hourly rate. Furthermore you can park your car at Heiligengeistfeld offering about 1,000 spaces. Availability and capacity depend on the events taking place on the fair grounds and parking fees amount to € 5.– per car and per day.

Public Transport

The CCH has good transport connections and central location:

- Rapid transit (S-Bahn) S11, S21, S31
- Underground (U-Bahn) U1, U2
- Bus lines 5, 109, 112, 3
- Express busses 34, 35, 36

For further information please visit www.hvv.de.

TRAVEL INFORMATION



© CCH - Congress Center Hamburg

IMPRINT

Publisher

Prof. Dr. med. Claus Garbe
University Skin Cancer Clinic Tuebingen
Liebermeisterstrasse 20
72076 Tuebingen, Germany

Prof. Dr. med. Axel Hauschild
University Hospital Schleswig-Holstein
Department of Dermatology
Campus Kiel
Schittenhelmstrasse 7
24105 Kiel, Germany

Editors

Prof. Dr. med. Claus Garbe
Prof. Dr. med. Axel Hauschild
MCI Deutschland GmbH

Graphic Design

MCI Deutschland GmbH, Berlin

Print

Ruksaldruck GmbH + Co. KG
Repro plus Offset, Berlin

Editorial Deadline

March 2013



Bristol-Myers Squibb
Oncology



Cancer is smart.

**We're seeking to make the
immune system smarter.**



Dedicated to visionary Immuno-Oncology science, Bristol-Myers Squibb is researching a diverse set of key Immuno-Oncology areas to harness the intelligence of the immune system to fight cancer.

To learn more, visit www.BMSImmunoOncology.com

 Bristol-Myers Squibb

SEE YOU IN HAMBURG.

www.worldmelanoma2013.com

